Evidence map›Paper›PMID 36100912›Full record

ArticleMalaria journal2022

Temporal trends in molecular markers of drug resistance in Plasmodium falciparum in human blood and profiles of corresponding resistant markers in mosquito oocysts in Asembo, western Kenya.

Zhiyong Zhou, John E Gimnig, Sheila B Sergent, Ying Liu, Bernard Abong'o, Kephas Otieno, Winnie Chebore, Monica P Shah, John Williamson, Feiko O Ter Kuile and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Malaria journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Pathogens (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Zhiyong ZhouDivision of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA. zaz6@cdc.gov.
John E GimnigDivision of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Sheila B SergentDivision of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Ying LiuDivision of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Bernard Abong'oCentre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Kephas OtienoCentre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Winnie CheboreCentre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Monica P ShahDivision of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
John WilliamsonDivision of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Feiko O Ter KuileDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Mary J HamelDivision of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Simon KariukiCentre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Meghna DesaiDivision of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Aaron M SamuelsDivision of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Edward D WalkerDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, USA.
Ya Ping ShiDivision of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA. yps0@cdc.gov.
Division of Parasitic Diseases and Malaria · USKenya Medical Research Institute · KECenter for Global Health · USCenters for Disease Control and Prevention · USLiverpool School of Tropical Medicine · GBMichigan State University · US

Funding

the US National Science Foundation #EF-0723770
6 · The paper itself

Abstract

backgroundOver the last two decades, the scale-up of vector control and changes in the first-line anti-malarial, from chloroquine (CQ) to sulfadoxine-pyrimethamine (SP) and then to artemether-lumefantrine (AL), have resulted in significant decreases in malaria burden in western Kenya. This study evaluated the long-term effects of control interventions on molecular markers of Plasmodium falciparum drug resistance using parasites obtained from humans and mosquitoes at discrete time points.

methodsDried blood spot samples collected in 2012 and 2017 community surveys in Asembo, Kenya were genotyped by Sanger sequencing for markers associated with resistance to SP (Pfdhfr, Pfdhps), CQ, AQ, lumefantrine (Pfcrt, Pfmdr1) and artemisinin (Pfk13). Temporal trends in the prevalence of these markers, including data from 2012 to 2017 as well as published data from 1996, 2001, 2007 from same area, were analysed. The same markers from mosquito oocysts collected in 2012 were compared with results from human blood samples.

resultsThe prevalence of SP dhfr/dhps quintuple mutant haplotype C

conclusionThis study showed an increased prevalence of dhfr/dhps resistant markers over 20 years with the emergence of Pfdhps-436H mutant a decade ago in Asembo. The reversal of Pfcrt from CQ-resistant to CQ-sensitive genotype occurred following 19 years of CQ withdrawal. No Pfk13 markers associated with artemisinin resistance were detected, but the increased haplotype of Pfmdr1 N

Indexed as

AntimalarialsArtemisininsCulicidaeMalaria, FalciparumAnimalsArtemetherArtemether, Lumefantrine Drug CombinationBiomarkersChloroquineDrug ResistanceHumansKenyaMosquito VectorsOocystsPlasmodium falciparumTetrahydrofolate DehydrogenaseAntimalarialsArtemetherArtemether, Lumefantrine Drug CombinationartemisininArtemisininsBiomarkersChloroquineTetrahydrofolate DehydrogenaseAsemboMosquitoesPfcrtPfk13Pfmdr1Plasmodium falciparumResistant markersSextuple dhfr/dhps mutantTrendWestern Kenya

Identifiers

PMID36100912
PMCPMC9472345
OpenAlexW4295419531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.